Before COVID-19, clinical trials supported the efficacy and safety of switching from IV to SC infliximab for patients with rheumatoid arthritis and inflammatory bowel disease (IBD), and SC infliximab may have been selected on the basis of patient and HCP preferences for SC agents.

Ferrara G et al. J Rheumatol 2018. doi: 10.3899/jrheum.171200

Therefore, they introduce a new treatment recommendation based on extramusculoskeletal manifestations, namely that tumor necrosis factor inhibitors are preferred in patients with a history of recurrent uveitis or active inflammatory bowel disease, whereas interleukin-17A inhibitors (IL-17i) are recommended in people with significant psoriasis.

The study included 109,085 patients with rheumatoid arthritis (RA; 49%) or inflammatory bowel disease (51%) from national registries in Denmark who were treated with biologic or nonbiologic therapy in 1995–2018.

Previously approved for the treatment of PsA, psoriasis, and inflammatory bowel disease in adults, ustekinumab may now be given to children aged 6 years and older with active PsA.

People with a history of colorectal cancer, inflammatory bowel disease, or immune-mediated inflammatory diseases were excluded from the study.

The recommendations also cover comorbidities with a potential influence on treatment, which are categorized into PsA-related conditions (inflammatory bowel disease [IBD] and uveitis) and other comorbidities.

A total of 1692 were on immunomodulatory therapy for an IMID – including rheumatic, inflammatory bowel, neurologic, and dermatologic diseases – and the control group comprised 473 IMID patients not taking immunosuppressants plus 174 healthy controls.

These people were sent annual questionnaires to ask about whether they had experienced new-onset physician-diagnosed RA, PMR, psoriasis, inflammatory bowel disease, or another autoimmune disease (with space to specify which).

TNF inhibitor monotherapy is associated with a lower risk for COVID-19-related hospitalization or death than other common immunomodulatory treatments given to people with immune-mediated inflammatory diseases, research suggests.

Authors: Sneha Patel & Anand Kumthekar Abstract Psoriatic arthritis (PsA) is associated with a higher burden of co-morbidities such as obesity, cardiovascular disease, non-alcoholic fatty liver disease, inflammatory eye disease, inflammatory bowel disease, skin cancer and depression compared to the general population.

Adalimumab-adbm is approved in the USA for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis, as well as other diseases including plaque psoriasis and inflammatory bowel disease. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

The agents, marketed under the brand names of Libmyris and Hukyndra , are indicated for the treatment of rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and juvenile idiopathic arthritis, as well as other immune-mediated diseases including uveitis and inflammatory bowel disease.

Most people with inflammatory diseases treated with immunomodulatory therapies mount an antibody response to mRNA vaccines against SARS-CoV-2, but the response may be blunted in those taking glucocorticoids or B cell-depleting therapies, shows the COVaRiPAD study.

People with immune-mediated inflammatory diseases, particularly those on rituximab or abatacept, may have a reduced antibody response to mRNA SARS-CoV-2 vaccines relative to the general population, show findings from a systematic review and meta-analysis.

Researchers report that secukinumab is associated with an increased risk for gastrointestinal-related adverse events in patients with ankylosing spondylitis and pre-existing inflammatory bowel disease and say that prescribing alternatives should be considered.

New S1PR modulators are under clinical development for MS, and their uses are being evaluated to treat other immune-mediated diseases, including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriasis.

There were no cases of inflammatory bowel disease among upadacitinib-treated patients. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EULAR 2021 Virtual Congress; 2–5 June

There were no reports of opportunistic infections, active tuberculosis, anaphylactic/serum sickness-like reaction, confirmed inflammatory bowel disease, or death during the COSMOS study. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group EULAR 2021 Virtual Congress; 2–5 June